If so, you may be entitled to compensation from a $30 million settlement.
0
days
This lawsuit concerns claims that Indivior violated certain state and federal laws which caused end payors to overpay for Suboxone. Indivior denies these claims and neither party has been declared right or wrong by the court. The parties have, however, agreed to settle this dispute for $30 million.
Plaintiffs allege that Indivior, Inc, while manufacturing and marketing the opioid addiction treatment drug (Co-Formulated Buprenorphine/Naloxone) hurt competition and violated state and federal laws resulting in harm to consumers and third-party payors in 11 states, who paid too much for Suboxone, brand and generic. Defendant denies these claims.
Indivior has agreed to a payment of $30 million to settle the litigation, which is subject to final approval by the Court. The Court will consider whether to grant final approval on October 19, 2023.
All persons or entities including third-party payers who purchased and/or paid for some or all of the purchase price for Co-Formulated Buprenorphine/Naloxone (Suboxone tablets, Suboxone film, or AB-rated generic equivalents of Suboxone (generic Suboxone)) in any form, for consumption by themselves, their families or their members, employees, plan participants, beneficiaries or insureds in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and District of Columbia between December 22, 2011 and August 21, 2023.
Excluded from the End Payor Class are the following:
Each qualifying claimant's share of the net settlement fund will be based on its qualifying purchases of Suboxone, and its AB-rated generic equivalents, and will be determined according to the proposed Plan of Allocation, if approved by the Court. Payments will be based on a number of factors, including but not limited to the number of valid claims filed and the dollar value of each member of the End Payor Class’s purchases in proportion to the total claims filed.
Disclaimer
Class members are not required to sign up with any third-party service in order to participate in the monetary relief, but may instead file their claim directly with the Class Administrator. No-cost assistance will be available from the Class Administrator and Class Counsel during the claims-filing period. For additional information class members may visit court approved website for this case, https://suboxantitrust.com/.
Please note this website and its contents are not substitutes for legal advice. Nothing in this website should be construed as legal advice. Class Action Settlement House, LLC works with companies to assist them in the filing of claims in various class action settlements. However, Class Action Settlement House, LLC is not a law firm and cannot provide legal representation or legal advice. If you are seeking legal advice, please contact counsel of your choice to obtain legal advice.